Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Impact on NAION A paper published in 2024 in JAMA Ophthalmology created shock waves in the ophthalmic community by showing that subcutaneous semaglutide was associated with a significantly higher risk of developing nonarteritic anterior ischemic optic neuropathy (NAION)
Abstract Semaglutide has shown benefit in metabolic dysfunction-associated steatohepatitis (MASH), but real-world evidence across longitudinal liver phenotypes remains limited, particularly regarding how liver remodeling relates to weight loss and dose exposure
Allows for gradual improvement : Doses can be increased based on how a persons body reacts
However, this isn't set in stone
K.et al (2020)
